A novel mouse model of cholangiocarcinoma uncovers a role for a SOX17-Tensin 4 pathway in tumor progression
M. Di-Luoffo, S. Pirenne, T. Saandi, A. Loriot, C. Gerard, N. Dauguet, F. Lamoline, K. Konobrocka, V. De Greef, M. Komuta, P. Jacquemin, F. P. Lemaigre
Abstract
Background & AimsAlthough earlier diagnosis and treatment of intrahepatic cholangiocarcinoma (iCCA) is necessary to improve therapy, there is still limited information available about initiation and evolution of iCCA precursor lesions. Therefore, there is a need to identify mechanisms driving formation of precancerous lesions and their progression towards invasive tumor using experimental models that faithfully recapitulate human tumorigenesis. MethodsWe generated a new mouse model which combines cholangiocyte-specific expression of KrasG12D with 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet-induced inflammation to mimic iCCA development in patients with cholangitis. Histological and transcriptomic analyses of the mouse precursor lesions and iCCA were performed and compared with human analyses. The function of genes overexpressed during tumorigenesis was investigated in human cell lines. ResultsMice expressing KrasG12D in cholangiocytes and fed a DDC diet developed cholangitis, ductular proliferations, intraductal papillary neoplasms of bile ducts (IPNBs) and eventually iCCAs. The histology of mouse and human IPNBs were highly similar, and mouse iCCAs displayed histological characteristics of human mucin-producing large duct type iCCA. Signaling pathways activated in human iCCA were activated in mice. The identification of transition zones between IPNB and iCCA on tissue sections, combined with RNA-sequencing analyses of the lesions supported that iCCAs derive from IPNBs. We provide evidence that a gene cascade which comprises KRASG12D, SRY-related HMG box transcription factor 17 (SOX17) and Tensin 4 (TNS4), and which is activated by epidermal growth factor, promotes tumor progression. ConclusionsWe developed a novel mouse model that faithfully recapitulates human iCCA tumorigenesis and identified a gene cascade promoting tumor progression.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- KRAS withdrawal in Cholangiocarcinoma leads to immune infiltration and tumor regression
Youwei Qiao, Matthew F. Yee, … Wen Xue·Advanced SciencePeer-reviewed·Dec 3, 2025
- Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma
R. K. Marcus, S. Ferri-Borgogno, … S. Gupta·bioRxiv·Oct 12, 2021
- In vivo modelling of patient genetic heterogeneity identifies concurrent Wnt and PI3K activity as a potent driver of invasive cholangiocarcinoma growth.
N. Younger, M. Wilson, … L. Boulter·bioRxiv·Jul 5, 2021
- NOTCH-YAP1/TEAD-DNMT1 axis regulates hepatocytereprogramming into intrahepatic cholangiocarcinoma
S. Hu, L. M. Molina, … S. Ko·bioRxiv·Dec 3, 2020
- The DNAJB1-PRKACA Oncogenic Fusion Drives Stepwise Biliary and Pancreatic Carcinogenesis from Intraductal Precursor Lesions
Patrick R. Carney, Manabu Nukaya, … Sean M. Ronnekleiv‐Kelly·bioRxiv·May 27, 2026
- Cell-of-Origin, not Oncogenic Effect, Determines esmoplastic Immune Exclusion in KRAS-Driven Liver Cancer
Chunshan Liu, Yule Wu, … Michael T. Dill·bioRxiv·Mar 26, 2026